Abstract: Background: The Clinical Trial for Uniform Multidrug Therapy for Leprosy Patients in Brazil (U-MDT/CT-BR), designed to evaluate the effectiveness of a six-months regimen, assessed the adverse effects caused by the drugs. oBjective: Describe adverse effects due to MDT in U-MDT/CT-BR, comparing the uniform regimen (U-MDT) to the current WHO regimen (R-MDT). Patients and methods: After operational classification, patients were randomly allocated to the study groups. U-MDT PB and U-MDT MB groups, received the U-MDT regimen, six doses of MB-MDT (rifampicin, dapsone and clofazimine). R-MDT PB and R-MDT MB groups, received the WHO regimens: six doses (rifampicin and dapsone) for PB and 12 doses (rifampicin, dapsone and clofazimine) for MB. During treatment, patients returned monthly for clinical and laboratorial evaluation. Patients with single lesion were not included in this trial. results: Skin pigmentation (21.7%) and xerosis (16.9%) were the most frequent complaints among 753 patients. Laboratory exams showed hemoglobin concentration lower than 10g/dL in 23.3% of the patients, glutamic oxaloacetic transaminase (GOT) above 40U/L in 29.5% and glutamic pyruvic transaminase (GPT) above 40U/L in 28.5%. Twenty-four patients (3.2%) stopped dapsone intake due to adverse effects, of whom 16.6% due to severe anemia. One case of sulfone syndrome was reported. study liMitations: Loss of some monthly laboratory sample collection. conclusions: There was no statistical difference regarding adverse effects in the R-MDT and U-MDT groups but anemia was greater in patients from R-MDT/MB group, therefore adverse effects do not represent a constraint to recommend the sixmonth uniform regimen of treatment for all leprosy patients.
INTRODUCTION
Leprosy is a neglected tropical disease, and remains a pub- However, AE caused by these drugs can be severe and discontinuation of treatment should be necessary in some patients.
Dapsone alone can cause methemoglobinemia, hemolytic anemia and other haematological disorders. Hepatitis, pancreatitis, and renal involvement may occur.
Although severe AE are rare, there are reports of several different AE. 1 A retrospective study in India, with 10,426 MB patients and 35,013 PB patients, reported 24 cases of severe AE, resulting in treatment discontinuation. 3 A prospective study, including 176 patients, reported 45% AE. 4 Retrospective studies with MDT in Brazil, reported 15% and 45% of AE. 5, 6 Dermatological problems, toxic hepatitis, hemolytic anemia, renal failure, and thrombocytopenia were the main cause of MDT discontinuation in other Brazilian studies. 7, 8 Another retrospective study found 19% of AE; 49% was related to hematological causes, and 50% to liver function. 9 In order to implement leprosy control in the field, WHO has made changes in the treatment duration. The number of doses for MB patients has been the main concern: the first guideline, in 1981, recommended 24 doses of MDT or, if possible, to treat until slit skin smears negativity. 1 Subsequently, 24 doses was recommended as a fixed duration treatment, and in 1998, WHO recommended 12 doses for MB patients. 10 Despite the MDT success, the long treatment duration, the difficulty to implement treatment, and the low adherence for treatment, reinforces the need for shorter treatment regimen. 11, 12 In 2002, the WHO Leprosy Expert Committee recommended pilot trials to evaluate the possibility of a uniform MDT regimen (U-MDT) with 6 doses of MDT-MB for all leprosy patients, independently of any classification.
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A multicenter clinical trial to assess the effectiveness of a U-MDT regimen was initiated in India and China in 2004. 14 Up to now, clinical improvement of PB patients, and good acceptability of MB patients are the main aspects observed. Moreover, the regimen was easier to implement in general health services. Another study conducted in India, concluded that the U-MDT was effective for treatment of PB patients but the follow up was not adequate to evaluate the efficacy for MB patients and it was not compared with MDT/ WHO. 15 No increase of relapses among MB patients treated with U-MDT was observed in a recent study conducted in Bangladesh. 16 To evaluate the effectiveness of the new treatment regimen 27 -34 pg. 18, 19 Data are expressed as mean ± SD. Analysis of Variance (ANOVA test was used for testing the significance of parametric data using SPSS, KAPLAN-MEIER test was used for analytical risk of anaemia, taken as the cut off value for significance as the limit for anemia was considered less or equal 10 for hemoglobin.
RESULTS
A total of 753 patients were enrolled in the study. cance. GTP and GOT were above 100 at any time during the treatment, in 18 and 36 patients, respectively. However, even in these patients, it was not necessary to interrupt the treatment.
There was no statistical significant difference among the study groups for GOT and GPT variation during treatment (Figure 1 ).
Severe AE were observed in 0.1% of all patients. The main Regardless of gender there was a decrease in the mean hemoglobin level during treatment in all arms of the study, particularly a month after the first MDT dose, with a gradual recover, p<0.0000.
The decrease was statistically significant among the study groups 
. Figure 3B shows that females had an increased risk for developing anemia (p< 0.0000).
Twenty-four patients (3.2%) stopped dapsone because of AE and received an alternative treatment; 16 (66.7%) had anemia, three patients of this group had leukopenia and two developed mild increase in the aminotransferases levels. Three patients (12.5%) developed erythroderma secondary to dapsone, and all these patients had mild anemia. Methemoglobinemia was diagnosed in one patient. Other reasons for MDT interruption were urticaria, headache and psychiatric disorder (Table 3) .
A ten-year-old boy was diagnosed with dapsone syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms -DRESS Syndrome). He developed exfoliative dermatitis, hepatosplenomegaly, fever, malaise and dyspnea. The blood tests revealed anemia (Hb = 7.2g/dL), leukocytosis (10900), increased levels of GOT (672) and GPT (919). Dapsone was stopped, and the patient was hospitalized. Thereafter, alternative MDT was introduced. Red blood cells, hematocrit and hemoglobin levels analysis recover when compared to those that received 12 doses. Moreover, it is important to emphasize the known fact that apparently healthier females tend to present more anemia than males. 21 The MCHC was the only parameter without significant alterations in the different arms of the study. A month after the first MDT dose, the MCV and MCH increased in all groups. This change was more evident in the PB/U-MDT group and remained higher during the whole treatment; similar results were observed in MB/R-MDT patients receiving 12 doses. Singh et al 4 also reported significant increase in MCV and MCH parameters but different from our results, reported statistically significant decrease of MCHC in patients receiving MDT.
DISCUSSION
In spite of the decrease in the blood hemoglobin levels, probably caused by dapsone, only 24 (2.8%) of our patients had to stop MDT. There are retrospective studies reporting higher frequencies of low blood hemoglobin levels related to dapsone: 18.7% and 24.2% in two different reports; these patients had to receive alternative treatments. 5, 9 A lower incidence -9 (11%) patients, was reported in a prospective study with 79 patients. 4 The intense monitoring of the patients and the immediate therapeutic action as established in our protocol, avoided the interruption of the treatment.
CONCLUSIONS
Skin pigmentation and xerosis were the most frequent adverse-effects associated with MDT. The similarities of AE in the four arms of the study points to the feasibility of a six-month uniform regimen.
Hematological changes were observed in the four arms of the study; it was detected one month after the first dose of MDT and remained changed during the whole treatment. The risk of anemia was greater in females, and MB patients treated with 12 doses were affected with a higher frequency.
The shorter duration of U-MDT treatment minimizes the AE, namely those secondary to dapsone.
Monthly monitoring enables early detection of AE, facilitating prompt interventions and unnecessary interruption or change of treatment.
Based on the present data it is possible to conclude that 
